Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Eurobio Scientific S.A. is a biotechnology company that specializes in the design, development, and commercialization of specialty in vitro diagnostic (IVD) tests. Its primary function is to provide innovative diagnostic solutions to healthcare professionals, aiding in the timely detection and management of diseases. The company's product portfolio encompasses a wide array of diagnostic tests that target infectious diseases, genetic disorders, and various chronic conditions. Eurobio Scientific’s offerings are crucial in medical settings such as hospitals, laboratories, and research facilities, where accurate and rapid diagnostic results are paramount. Headquartered in France, Eurobio Scientific plays a significant role in the healthcare sector by advancing diagnostic technologies and improving patient outcomes. Through strategic partnerships and continuous research and development, the company maintains its presence in the European market and is poised to expand its reach, contributing to the global healthcare landscape.
Operating margin is thin at 6.37%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 9.1%, steady but not accelerating. Free cash flow declined 53% despite revenue growth, conversion is weakening.
Free cash flow declined 53% versus the prior year, cash generation momentum has weakened.
Profitability & Returns
Revenue (TTM)
€169M
▲ +9.1% YoY
Net Income (TTM)
€5M
▲ +21.7% YoY
Op. Margin
6.37%
ROIC
3.42%
▲ +0.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€6M
▼ -53.3% YoY
Op. Cash Flow (TTM)
€19M
▲ +13.9% YoY
Net Debt
-€5M
Net Cash Position
Cash & Equiv.
€21M
3Y CAGR: +3.4%
3Y CAGR: -46.2%
Continue Research